CIRRHOTIC CARDIOMYOPATHY. REVIEW ARTICLE
Keywords:
Liver cirrhosis, blood pressure, cirrhotic cardiomyopathy, hepatorenal syndrome, systolic and diastolic stomach disorders, zinc protoporphyrinAbstract
Liver cirrhosis is associated with numerous cardiovascular disorders. They include increased heart function and lower blood pressure and total peripheral vascular resistance. In these patients, despite an increase in the work of the heart, systolic and diastolic function deteriorates in the framework of pharmacological, physiological and surgical stresses, as well as the electrical activity of the myocardium, most often in the form of lengthening the QT interval. These deviations are combined into the concept of cirrhotic cardiomyopathy. It is believed that cirrhotic cardiomyopathy contributes to the cardiac dysfunction that is seen in patients with intrahepatic portosystemic stent shunts and liver transplants. Insufficient contractile function of the heart may play a role in the pathogenesis of hepatorenal syndrome, which rapidly leads to spontaneous bacterial peritonitis.
References
Soon, K. Baik1, Tamer R Fouad, Samuel S Lee. Cirrhotic cardiomyopathy. Orphanet Journal of Rare Diseases.- 2007.- 2:15.-1750-1172.
Kowalski, HJ, Abelman WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest. 1953.- 32(10). Р.-1025–1033.
Abelmann, WH, Kowalski HJ, McNeely WF. The hemodynamic response to exercise in patients with Laennec’s cirrhosis. Clin Invest.- 1955.- 34.-Р.690-695.
Day, CP, James OF, Butler , Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet.- 1993.- 5.-1423-1428.
Rayes, N, Bechstein WO, Keck H et all. Causes of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralblatt Chir 1995.-120.-P.435–438
Bernardi, M, Calandra S, Colantoni A et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology.1998.-27(1).- P.28-34.
Lee, SS. Cardiac abnormalities in liver cirrhosis. West J Med .- 1989.-151.-P. 530–539.
Laffi, G, Barletta G, La Villa G et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology.- 1997.-113.-P. 891–898. 9. Wong, F, Girgrah N, Graba J et al. The effect of cirrhotic cardiomyopathy on the cardiac response to exercise in cirrhosis. Gut.- 2001.-49.-P.268–275.
Moreau, R, Hadengue A, Soupison T et al. Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanism. Hepatology.- 1990.- 12.-P.7–12.
Wong, F, Liu P, Lilly L et al. The role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci.- 1999.-97. P.259–267.
Møller, S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut.- 2008.-57.- P. 268–278.
Xiao, RP, Cheng H, Zhou YY et al. Recent advances in cardiac beta-adrenergic signal transduction. Circ Res. – 1999.- 85.-P.1092–1100.
Alqahtani, SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Sem Liver Dis.- 2008.-28.-P.59–69.
Ward, C.A., Ma Z., Lee S.S. et al. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis.Am J Physiol.- 1997.-273.-P. 537-544.
Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol.- 1997.-26.-P.904–912.
Ma, Z, Miyamoto A, Lee SS. Role of altered betaadrenoreceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996.- 110.- P.1191–1198.
Devane, W.A. ,Miyamoto A, Lee SS.et al. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 1988.- 34(5).-P.605-613.
Caraceni, P, Domenicali M, Bernardi M. The endocannabinoid system and liver diseases. J Neuroendocrinol.- 2008.-20.-P.47–52.
Gaskari, SE, Liu H, Moezi L et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct ligated rats. Br J Pharmacol.- 2005.-146.-P.315–323.
Batkai, S, Mukhopadhyay P, Harvey-White J et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol.-2007.-293.-P.1689–1695.
Liu, H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology.- 2000.-118.-P. 937–944.
Liu, H, Song D, Lee SS. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol Gastrointest Liver Physiol.- 2001.-280.- P.68–74. В помощь практикующему врачу 122
Liu, H, Lee SS. Nuclear factor-kappa B inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int.- 2008.-28.-P.640–648.
Lin, RS, Lee FY, Lee SD et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol.- 1995.-22.-P.165–172.
Ma, Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology.- 1996.- 24.- P.451-459.
Liu, H, Lee SS. Cardiopulmonary dysfunction in cirrhosis. J Gastroenterol Hepatol.- 1999.- 14.-P.600-608.
Zhong, J, Hwang TC, Adams HR et al. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol.- 1997.- 273.-P.2312–2324.
Gould, L, Shariff M, Zahir M et al. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest.- 1969.-48.-P. 860–868
Kelbaek, H, Eriksen J, Brynjolf I et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol.- 1984.-54.-P.852–855.
